Immunosuppressive Medication Adherence in Patients With Hepatocellular Cancer Who Have Undergo Liver Transplantation: A Case Control Study

Basit Öğe Kaydı
dc.authoridSarıtaş, Serdar/0000-0003-4076-9001
dc.authoridAkbulut, Sami/0000-0002-6864-7711
dc.authoridTamer, Murat/0000-0001-9142-1844
dc.authorwosidSarıtaş, Serdar/ABG-8413-2020
dc.authorwosidAkbulut, Sami/L-9568-2014
dc.contributor.authorAkbulut, Sami
dc.contributor.authorTamer, Murat
dc.contributor.authorSaritas, Serdar
dc.contributor.authorUnal, Ozlem
dc.contributor.authorAkyuz, Musap
dc.contributor.authorUnsal, Selver
dc.contributor.authorKucukakcali, Zeynep
dc.date.accessioned2024-08-04T20:53:40Z
dc.date.available2024-08-04T20:53:40Z
dc.date.issued2023
dc.departmentİnönü Üniversitesien_US
dc.description.abstractBackground. We aimed to compare the adherence to immunosuppressive medication use in patients who underwent liver transplantation (LT) due to hepatocellular carcinoma (HCC) and non-HCC reasons.Methods. The study population was determined as 242 patients with HCC and 1290 patients with non-HCC who had LT performed in our institute between March 2002 and November 2021; all these patients were contacted by phone in March 2022. The sample size was calculated using the MedCalc software program, and the number of patients required in each group was determined as 111 patients. Furthermore, we used the sample.int function, a random integer generator in the R (version 4.1.2) software program. Whereas demographic and clinical parameters were determined as independent variables, the immunosuppressive medication adherence scale (IMAS) score was determined as a dependent variable. Patients were evaluated by the IMAS. This 11-item IMAS scale evaluates the lowest compliance score as 11 and the highest as 55.Results. Out of a total number of 221 patients, 161 (72%) were men and 60 (27.1%) were women, with a median age of 58 years (IQR: 14); one patient in the non-HCC group was excluded due to lack of data. Among the HCC and non-HCC groups, significant differences were found in terms of the variables of age (P = .003), IMAS score (P < .001), sex (P = .001), working status (P = .004), chronic diseases (P = .008), tacrolimus alone (P < .001), tacrolimus plus everolimus (P < .001), and often medication changes (P < .001). A statistically significant correlation was found between the IMAS score and whether the patients had HCC (P < .001) and frequently changing immunosuppressive drugs (P = .023).Conclusion. This study showed that patients with frequent drug changes or non-HCC etiology had better adherence to immunosuppressive drug use.en_US
dc.identifier.doi10.1016/j.transproceed.2023.02.064
dc.identifier.endpage1238en_US
dc.identifier.issn0041-1345
dc.identifier.issn1873-2623
dc.identifier.issue5en_US
dc.identifier.pmid37080874en_US
dc.identifier.scopus2-s2.0-85152955113en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage1231en_US
dc.identifier.urihttps://doi.org/10.1016/j.transproceed.2023.02.064
dc.identifier.urihttps://hdl.handle.net/11616/101299
dc.identifier.volume55en_US
dc.identifier.wosWOS:001035813300001en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherElsevier Science Incen_US
dc.relation.ispartofTransplantation Proceedingsen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectRecurrenceen_US
dc.subjectCarcinomaen_US
dc.subjectNonadherenceen_US
dc.subjectTherapyen_US
dc.subjectRecipientsen_US
dc.subjectOutcomesen_US
dc.subjectImpacten_US
dc.subjectRisken_US
dc.titleImmunosuppressive Medication Adherence in Patients With Hepatocellular Cancer Who Have Undergo Liver Transplantation: A Case Control Studyen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu